ArticleJournal of experimental & clinical cancer research : CR2018

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma.

Irene Ferrer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.